<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792462</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2023-YX-012-01</org_study_id>
    <nct_id>NCT05792462</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders</brief_title>
  <official_title>Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral&#xD;
      immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus&#xD;
      kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with&#xD;
      neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation&#xD;
      and differentiation. Baricitinib may benefit some patients with NMOSD due to the important&#xD;
      role of B cells in the pathogenesis of NMOSD. Clincial trials may be needed to observe its&#xD;
      efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators primarily aim to observe the time to first relapse from initiation of&#xD;
      baricitinib treatment.&#xD;
&#xD;
      The secondary outcomes are to determine: The safety profile of baricitinib in participants&#xD;
      with NMO and whether baricitinib improves Expanded Disability Status Scale (EDSS), et al.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2023</start_date>
  <completion_date type="Anticipated">September 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First time to relapse</measure>
    <time_frame>From baseline to one year after</time_frame>
    <description>An acute attack was defined as a new neurological worsening lasting for at least 24 hours and occurring more than 30 days after the previous attack</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in EDSS</measure>
    <time_frame>Changes in EDSS from baseline to 52 weeks</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) is a rating system that is frequently used for classifying and standardizing the severity and progression. EDSS ranges from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Optic nerve,brain and spinal cord Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>The total number of new and/or enlarging T2 lesions for all participants was calculated as the sum of the individual number of lesions at Weeks 12, 24, and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peripheral blood B cell subsets</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>Compare peripheral blood plasma cells before and one year after initial intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum AQP4 antibodies</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>Compare serum AQP4-ab titers before and one year after initial intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>Adverse events related to belimumab are recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>NMO Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib will be taken orally with a dose of 2mg once daily until the disease relapses or week 48, with a final evaluation at week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.</description>
    <arm_group_label>Baricitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients â‰¥ 18 years old;&#xD;
&#xD;
          2. Diagnosis of NMO or NMO spectrum disorder according to the 2015 International&#xD;
             diagnostic criteria for neuromyelitis optic;&#xD;
&#xD;
          3. Clinical evidence of either at least one attack requiring rescue therapy (intravenous&#xD;
             corticosteroids,intravenous immunoglobulin,plasma exchange,or a combination of these&#xD;
             therapies) or at least two attacks requiring rescue therapy in the 2 years before&#xD;
             screening;&#xD;
&#xD;
          4. EDSS &lt;=6.0;&#xD;
&#xD;
          5. Able and willing to give written informed consent and comply with the requirements of&#xD;
             the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current evidence or known history of clinically significant infection (Herpes simplex&#xD;
             virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human&#xD;
             immunodeficiency virus, Hepatitis viruses, Syphilis, etc);&#xD;
&#xD;
          2. Participation in another interventional trial within the last 3 months Tumor disease&#xD;
             currently or within last 5 years;&#xD;
&#xD;
          3. Pregnant, breastfeeding, or child-bearing potential during the course of the study&#xD;
             Clinically relevant heart, liver, kidney or bone marrow function disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing Liu, M.D.,Ph.D.</last_name>
    <phone>+86 15022439149</phone>
    <email>qliu@tmu.edu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiang Liu, M.D.,Ph.D.</last_name>
      <phone>+8615022439149</phone>
      <email>qliu@tmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Qiang Liu, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 18, 2023</study_first_submitted>
  <study_first_submitted_qc>March 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Qiang Liu</investigator_full_name>
    <investigator_title>Professor of Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

